An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

NCT02667587 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

716

Enrollment

INDUSTRY

Sponsor class

Conditions

Brain Neoplasms

Interventions

DRUG: Nivolumab
DRUG: Temozolomide
RADIATION: Radiotherapy
OTHER: Nivolumab Placebo

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]